Public, NASDAQ:GNLB
NASDAQ Capital Market
Gilead ends hepatitis C research deal with Genelabs Technologies
Date: Tue, 24 Jun 2008 12:43:09 GMT
Tags:
Gilead ends hepatitis C research deal with Genelabs Technologies
Milwaukee Business Journal - Jun 24, 2008
Milwaukee Business Journal - Jun 24, 2008
Genelabs Technologies Inc . said Monday that Gilead Sciences Inc . ended a deal between the two companies to study a possible hepatitis C treatment.Redwood City - based Genelabs ( NASDAQ : GNLB ...
Gilead ends hepatitis C research deal with Genelabs Technologies
Date: Mon, 23 Jun 2008 19:36:01 GMT
Tags:
Gilead ends hepatitis C research deal with Genelabs Technologies
MSN Money - Jun 23, 2008
Gilead ends HCV research collaboration with Genelabs - MSN Money
Business Wire (press release)
MSN Money - Jun 23, 2008
Genelabs Technologies Inc . said Monday that Gilead Sciences Inc . ended a deal between the two companies to study a possible hepatitis C treatment.Redwood City - based Genelabs ( NASDAQ : GNLB ...
Genelabs says Gilead has terminated research collaboration agreement - ForbesGilead ends HCV research collaboration with Genelabs - MSN Money
Business Wire (press release)
Market Report -- In Play (WIRES)
Date: Fri, 06 Jun 2008 13:46:42 GMT
Tags:
Market Report -- In Play (WIRES)
MSN Money - Jun 6, 2008
MSN Money - Jun 6, 2008
On The Wires Genelabs Technologies ( GNLB ) announces that a presentation was made today at the International Workshop on Hepatitis C , Resistance and New Compounds on a non - nucleoside hepatitis ...
Genelabs Technologies Announces Presentation of Data on Non-Nucleoside HCV Polymerase Inhibitor at 3rd International Workshop
Date: Fri, 06 Jun 2008 13:19:05 GMT
Tags:
Genelabs Technologies Announces Presentation of Data on Non-Nucleoside HCV Polymerase Inhibitor at 3rd International Workshop
PR-Inside.com (Pressemitteilung) - Jun 6, 2008
PR-Inside.com (Pressemitteilung) - Jun 6, 2008
www . genelabs . com - Genelabs Technologies , Inc . ( Nasdaq : GNLB ) announced that a presentation was made today at the 3rd International Workshop on Hepatitis C , Resistance and New Compounds ...
Genelabs Q1 loss more than doubles
Date: Wed, 14 May 2008 14:39:22 GMT
Tags:
Genelabs Q1 loss more than doubles
MSN Money - May 14, 2008
Genelabs Q1 loss more than doubles Silicon Valley / San Jose Business Journal - Bizjournals.com
Business Wire (press release) - RTT News - RTT News
MSN Money - May 14, 2008
Genelabs Technologies Inc . on Wednesday reported a first quarter loss of $1.8 million , or 4 cents a share , compared to a loss in the same period last year of $500,000 , or 2 cents a share.The ...
Genelabs Q1 loss widens despite higher revenues; unveils progress on Operational Priorities - Update - RTT NewsGenelabs Q1 loss more than doubles Silicon Valley / San Jose Business Journal - Bizjournals.com
Business Wire (press release) - RTT News - RTT News
GENELABS TECHNOLOGIES INC /CA Files SEC form 8-K, Changes in Registrant's Certifying Accountant (EDGAR Online)
Date: Thu, 10 Jul 2008 15:21:09 Etc/GMT
Tags:
GENELABS TECHNOLOGIES INC /CA Files SEC form 8-K, Termination of a Material Definitive Agreement (EDGAR Online)
Date: Mon, 23 Jun 2008 21:18:34 Etc/GMT
Tags:
Gilead ends hepatitis C research deal with Genelabs Technologies (at bizjournals.com)
Date: Mon, 23 Jun 2008 18:55:05 Etc/GMT
Tags:
Gilead ends HCV research collaboration with Genelabs (at bizjournals.com)
Date: Mon, 23 Jun 2008 14:45:09 Etc/GMT
Tags:
Genelabs Provides Update on Hepatitis C Drug Development With Collaboration Partners (Business Wire)
Date: Mon, 23 Jun 2008 13:00:00 Etc/GMT
Tags:
REDWOOD CITY, Calif.----Genelabs Technologies, Inc. announced today that based on progress to date, its hepatitis C drug development and commercialization collaboration with Novartis is continuing to the next phase.